Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562416 · ClinicalTrials.gov registry record · Phase 2
Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects
A Phase 2 study, sponsored by Temple University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03562416 is a Phase 2 study that was terminated before completion, run by Temple University. The registered enrollment target is 1 participants.
The verdict
NCT03562416, a Phase 2 study, was terminated before completion, sponsored by Temple University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The aim of this study is to assess the utility of nintedanib therapy in addition to usual transplant care in single lung transplant recipients with idiopathic pulmonary fibrosis (IPF). The investigators hypothesize that in IPF subjects who undergo single lung transplantation the administration of nintedanib 150 mg twice daily in addition to usual transplant care will result in better preservation of lung function at 24 months.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-07-05 |
| Est. Completion | 2021-12-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03562416
The ClinicalTrials.gov registry entry for NCT03562416 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Temple University, which has 163 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03562416 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03562416 about?
NCT03562416 is a clinical study titled "Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects". The aim of this study is to assess the utility of nintedanib therapy in addition to usual transplant care in single lung transplant recipients with idiopathic pulmonary fibrosis (IPF). The investigators hypothesize that in IPF subjects who undergo single lung transplantation the administration of ni...
What is the current status of trial NCT03562416?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-07-05. Estimated completion is 2021-12-21.
What interventions are being tested in trial NCT03562416?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Nintedanib (DRUG).
Who is sponsoring clinical trial NCT03562416?
This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.